Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
McFall T, Trogdon M, Guizar A, Langenheim J, Sisk-Hackworth L, Stites E. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. Npj Precision Oncology 2022, 6: 86. PMID: 36418474, PMCID: PMC9684405, DOI: 10.1038/s41698-022-00329-w.Peer-Reviewed Original Research